Finance

Lists
ALXO:NASDAQ
ALX Oncology Holdings Inc
$1.14
0.00%
(0.00) 1D
$1.09
-4.39% (-0.050)
Pre-market
Closed: Oct 19, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ALXO...
Mkt. cap
142.41M
Avg. vol.
1.45M
Volume
18.85K
52-wk high
$2.66
52-wk low
$0.86
EPS
-$1.14
Beta
0.47
Shares outstanding
138.28M
No. of employees
48
Mkt. cap
142.41M
Avg. vol.
1.45M
Volume
18.85K
52-wk high
$2.66
52-wk low
$0.86
EPS
-$1.14
Beta
0.47
Shares outstanding
138.28M
No. of employees
48
News stories
From web sources and news partners
About ALX Oncology Holdings Inc
CEO-
Employees48
Founded2015
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websitealxoncology.com
Analyst ratings
Based on 4 analysts giving stock ratings to ALXO in the past 3 months
Strong buy
Buy
3
Hold
1
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for ALXO in the last 3 months.
Highest
Current $1.14
$5.00 (+338.60%)
Average
$4.33 (+279.82%)
Lowest
$4.00 (+250.88%)
Analyst
Recommendation
Action
Price target
Projected
Date
Derek Archila
Wells Fargo
Buy
Maintained
$5.00
+338.6%
10/16/2026
Swayampakula Ramakanth
H.C. Wainwright
Buy
Reiterated
$4.00
+250.9%
10/01/2026
Allison Bratzel
Piper Sandler
Buy
Maintained
$4.00
+250.9%
08/17/2026
Sam Slutsky
LifeSci Capital
Hold
Maintained
-
-
08/06/2026
Michael Yee
UBS
Buy
Maintained
$6.00
+426.3%
05/12/2026
Last report
Aug 6, 2026
Fiscal period
Q2 2026
-$0.11 / -$0.16
+32.46%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
17.44M
17.64M
13.61M
13.14M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.09M
5.38M
5.36M
5.13M
Operating expense
22.53M
23.02M
18.97M
18.27M
Total operating expenses
22.53M
23.02M
18.97M
18.27M
Operating income
-22.53M
-23.02M
-18.97M
-18.27M
Other non operating income
-
-
188.00K
-
EBT including unusual items
-22.14M
-22.85M
-17.93M
-17.97M
EBT excluding unusual items
-22.14M
-22.85M
-17.93M
-17.06M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-22.14M
-22.85M
-17.93M
-17.97M
Net profit margin
-
-
-
-
Earnings per share
-
-0.37
-0.15
-0.11
Interest and investment income
802.00K
573.00K
1.18M
1.51M
Interest expense
-408.00K
-383.00K
-331.00K
-285.00K
Net interest expenses
394.00K
190.00K
851.00K
1.22M
Depreciation and amortization charges
-
-
-
-
EBITDA
-22.38M
-22.87M
-18.82M
-17.71M
Gain or loss from assets sale
-
-
-
246.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps